GSK has announced plans to invest USD 30 billion across the United States over the next five years, aimed at strengthening its R&D and supply chain infrastructure.   

This includes a new USD 1.2 billion investment in advanced manufacturing facilities and AI and advanced digital technologies, to deliver new, next-generation biopharma factories and laboratories. As part of this project, GSK will build a new biologics flex factory at Upper Merion, Pennsylvania, with construction planned to commence in 2026. The site will focus on potential best-in-class new medicines for respiratory disease (COPD, asthma) and cancer (haematological, gynaecological, lung and other solid tumours).

Furthermore, the USD 1.2 billion investment will fund the introduction of new AI and advanced digital capabilities across GSK’s five existing manufacturing sites in Pennsylvania, North Carolina, Maryland, and Montana, along with expanded drug substance manufacturing capacity and enhanced device, auto-injector, and assembly capabilities.  

“Alongside the many longstanding and vital shared interests that connect the UK and the United States, is advancing life sciences to get ahead of disease. This week’s State Visit brings together two countries that have led the world in science and healthcare innovation.  We are proud to be part of both,” said GSK CEO Emma Walmsley.

“In the UK, we continue to invest in a significant manufacturing base and more than GBP 1.5 billion in R&D every year. Today, we are committing to invest at least USD 30 billion in the United States over the next five years, further bolstering the already strong R&D and supply chain we have in the country,” she added.

GSK’s planned USD 30 billion investment covers capital investments across its US supply chain, increased funding for R&D, drug discovery, development, and clinical trial activity.

Over the last 12 months, GSK has committed new investments of approximately USD 2 billion in US manufacturing. In October 2024, construction began on a new USD 800 million facility at GSK’s Marietta, Pennsylvania site, doubling the size and capacity of the site.

Last year, GSK’s global supply chain network delivered 1.7 billion packs of medicines and over 400 million vaccine doses, supporting its goal of positively impacting the health of 2.5 billion people by the end of 2030.